Given that AKAP12 was negatively linked with anti-VEGF therapy sensitivity in OV, GBM, LUSC, and CRC, we proposed that AKAP12 might promote resistance via the recruitment and activation of CAFs. Here, VEGFA is linked to glioblastoma.